Suppr超能文献

研究假设:年龄、性别、糖尿病或高血压的存在以及抗高血压药物是 COVID-19 死亡率的独立危险因素。

STUDY HYPOTHESIS: AGE, GENDER, PRESENCE OF DIABETES MELLITUS OR HYPERTENSION, AND ANTI-HYPERTENSIVE DRUGS ARE INDEPENDENT RISK FACTORS FOR COVID-19 MORTALITY.

机构信息

Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Department of Internal Medicine, Istanbul, Turkey.

Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Department of Infectious Diseases, Istanbul, Turkey.

出版信息

Acta Clin Croat. 2023 Nov;62(3):447-456. doi: 10.20471/acc.2023.62.03.6.

Abstract

We aimed to investigate the effects of comorbid diseases and antihypertensive drugs on the clinical outcome of hospitalized patients with COVID-19 infection. A total of 1045 patients whose data could be gathered and confirmed from both hospital files and Turkish National Health Network records were retrospectively screened, and 264 of 1045 patients were excluded because of having more than one comorbid disease. The study population consisted of a total of 781 patients, of which 482 had no comorbid disease, while the remaining 299 patients had only one comorbid disease. The mortality risk was 7.532 times higher in those over 65 years of age compared to cases younger than 30 years (OR: 7.532; 95% CI: 1.733-32.730); the risk of mortality in men was 2.131 times higher than in women (OR: 2.131; 95% CI: 1.230-3.693); and presence of diabetes mellitus (DM) increased mortality risk 2.784 times (OR: 2.784; 95% CI: 1.288-6.019). While hypertension was not found to be an independent risk factor for COVID-19 mortality, age, gender, and presence of DM were independent risk factors for COVID-19 mortality. There was no association between antihypertensive drugs and mortality. Accordingly, age (>65 years), gender (male), and presence of DM were independent risk factors for COVID-19 mortality, whereas hypertension and use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and their combinations with other antihypertensive drugs were not risk factors for COVID-19 mortality.

摘要

我们旨在研究合并症和降压药物对 COVID-19 感染住院患者临床结局的影响。回顾性筛选了总共 1045 名可以从医院档案和土耳其国家卫生网络记录中收集和确认数据的患者,其中 264 名患者因患有多种合并症而被排除在外。研究人群共包括 781 名患者,其中 482 名患者无合并症,而其余 299 名患者仅有一种合并症。与 30 岁以下的患者相比,65 岁以上患者的死亡风险高 7.532 倍(OR:7.532;95%CI:1.733-32.730);男性的死亡风险比女性高 2.131 倍(OR:2.131;95%CI:1.230-3.693);糖尿病(DM)的存在使死亡率增加了 2.784 倍(OR:2.784;95%CI:1.288-6.019)。虽然高血压不是 COVID-19 死亡的独立危险因素,但年龄、性别和 DM 的存在是 COVID-19 死亡的独立危险因素。降压药物与死亡率之间没有关联。因此,年龄(>65 岁)、性别(男性)和 DM 的存在是 COVID-19 死亡的独立危险因素,而高血压以及使用血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂及其与其他降压药物的联合用药不是 COVID-19 死亡的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45e7/11413996/a3389155f0fe/acc-62-447-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验